We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Advanced MRI Marks Breakthrough for Patients with Heart Stiffening Disease

By MedImaging International staff writers
Posted on 31 Jul 2022
Print article
Image: Stiff heart syndrome occurs when plaques of protein called amyloid build up in heart muscle (Photo courtesy of University College London)
Image: Stiff heart syndrome occurs when plaques of protein called amyloid build up in heart muscle (Photo courtesy of University College London)

Light-chain cardiac amyloidosis (stiff heart syndrome) is a life-limiting condition that occurs when plaques of protein called amyloid build up in heart muscle, affecting its ability to pump blood, and without treatment can rapidly lead to heart failure and death. However, assessing the condition has been difficult, as while clinicians can detect the presence of amyloid in the heart, there has been no safe test to measure the amount. This has also meant there has been no way of measuring the therapeutic effect of chemotherapy – the normal first line treatment. A patient’s response is currently assessed with indirect biological markers, but these do not measure the amount (or reduction) of cardiac amyloid – the drug’s ultimate target – and doctors find the markers less useful when trying to assess second-line chemotherapy treatments. Now, an advanced form of cardiac MRI has for the first-time enabled clinicians to measure the effectiveness of chemotherapy in patients with ‘stiff heart syndrome’.

Researchers at University College London (London, UK) have, for 10 years, been developing and refining Cardiovascular Magnetic Resonance (CMR) Extracellular Volume Mapping (ECV) for amyloid. This non-invasive technique enables clinicians to measure both the presence and amount of amyloid protein using MRI. Now for the first time they have used the technology to evaluate the success of chemotherapy treatment, by assessing cardiac amyloid regression or progression.

For the study 176 patients with light-chain cardiac amyloidosis had Cardiovascular Magnetic Resonance with Extracellular Volume Mapping. CMR scans with ECV mapping were done at diagnosis, and then at six, 12 and 24 months after starting chemotherapy. The advanced MRI technique allowed researchers to accurately measure the amount of amyloid protein in hearts, and, for the first-time ever, to measure the changes in response to chemotherapy on repeat scans. By measuring the changes they could detect which patients would have a better or worse prognosis. Further, combining the results with blood tests for the disease, it was found almost 40% of patients had a substantial improvement (reduction) in amyloid deposition, something that was not thought to be possible before – showing how effective chemotherapy can be. The researchers believe that the MRI technique should now be used immediately to diagnose and assess all cases of light-chain cardiac amyloidosis.

“Since MRI scans are widely available, by developing the use of ECV mapping in a machine that already is used for these patients, we hope that its use can be made available to more patients to help improve their care,” said Professor Marianna Fontana (UCL Division of Medicine), senior author and a British Heart Foundation (BHF) Clinical Fellow. “The aim would be to use these scans routinely for all patients with the disease to help doctors monitor the response to chemotherapy to help improve patient survival, which is very poor in patients who do not respond to treatment.”

Related Links:
University College London 

New
Gold Supplier
Conductive Gel
Tensive
New
Densitometry & Data Management Solution
QuickScan Touch Plus
New
Ceiling Suspension Tubestand
Lem Plus iC
New
CT Injector Syringe
MDT CT Injector Syringe

Print article
Sun Nuclear -    Mirion
FIME - Informa

Channels

Radiography

view channel
Image: BiOI ruby-like crystals can improve medical imaging safety by lowering intensities of harmful X-rays (Photo courtesy of University of Cambridge)

Sustainable Solar Cell Material Could Revolutionize Medical Imaging

The use of X-rays for internal body imaging has dramatically changed non-invasive medical diagnostics. Yet, the high dose of X-rays required for these imaging techniques, due to the poor performance of... Read more

Ultrasound

view channel
Image: A new study has shown the value of endoscopic ultrasound in NSCLC (Photo courtesy of Freepik)

Endoscopic Ultrasound Can Provide Value in NSCLC, Finds Study

The usefulness of confirmatory mediastinoscopy following tumor-negative results on endoscopic ultrasound still remains debatable among researchers. This procedure is often employed for mediastinal staging... Read more

Nuclear Medicine

view channel
Image: New imaging method offers potential for diagnosing, staging, and treating multiple types of cancer (Photo courtesy of SNMMI)

New Imaging Method Superior for Diagnosing Multiple Types of Cancer

Cancer-associated fibroblasts play a significant role in tumor development, migration, and progression. A subset of these fibroblasts expresses fibroblast activation protein (FAP), a protein prominently... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The global AI-enabled medical imaging solutions market is expected to reach USD 18.36 billion in 2032 (Photo courtesy of Freepik)

Global AI-Enabled Medical Imaging Solutions Market Driven by Need for Early Disease Detection

The AI-enabled medical imaging solutions market is currently in its developmental stages, following the significant role of AI-based tools in combating the COVID-19 pandemic. The pandemic saw an upswing... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.